Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer (CRPC).

Several therapies that have demonstrated similar efficacy are available to treat men with nonmetastatic CRPC, Slovin says. Without comparative data, safety should be a key consideration for treatment selection. Additionally, potential sensitivity, allergic reactions, and drug-drug interactions should be carefully reviewed prior to selecting, Slovin says.

Guidelines should also be followed to determine whether a patient is more likely to respond to a particular therapy vs another. In general, however, all available options to treat nonmetastatic CRPC are reasonable choices. Ultimately, treatment selection should be based on physician expertise and individual patient characteristics to optimize therapy, Slovin concludes.